Australia TGA Medical Device UDI Requirements Begin Phased Implementation on 1 July 2026

Source Information

• Source authority: Therapeutic Goods Administration (TGA), Australia
• Original publication date: 1 July 2026
• Site publication time: 8 July 2026, 09:00
• Original link: https://www.tga.gov.au/news/news-articles/new-udi-requirements-medical-devices-commence-1-july-2026

TGA Phased UDI Requirements Take Effect

The Australian TGA has announced that certain medical devices supplied in Australia must meet unique device identification (UDI) requirements from 1 July 2026. The first phase covers Class IIb and Class III high-risk devices, with subsequent expansion to other device categories and IVD products.

Full Translation of the Core Original Content

According to the TGA page, the new UDI requirements for medical devices will be implemented in phases from 1 July 2026. The first stage primarily covers certain Class IIb and Class III medical devices and will gradually extend to other categories and IVD products.

The core objective of the UDI requirements is to enhance product traceability, regulatory database management, post-market surveillance, recall capability and supply chain identification through unique device identification. Companies need to focus on device identifiers, packaging levels, database submissions, label updates, ARTG information consistency and the implementation timetable.

For companies planning to enter the Australian market or already selling in Australia, UDI is not merely a matter of applying a code. It is a systemic requirement involving registration dossiers, labels, supply chain, distributors and post-market management working together.

AIMEILI Regulatory Interpretation

AIMEILI Regulatory Affairs believes that updates of this kind reflect a global regulatory shift from pre-market access toward life-cycle transparency management. UDI, EUDAMED, SSCP, adverse event terminology and electronic reporting systems appear to belong to different regulatory modules, but they all point to one requirement: after a product is placed on the market, it must be identifiable, traceable, updatable and publicly explainable, and companies must be able to demonstrate ongoing compliance with structured data.

For companies, this is not a question of a single label field or database account. It is an integrated engineering task linking registration dossiers, packaging labels, ERP codes, distributor management, PMS plans, complaint handling, recall processes and certificate maintenance. If the model on the registration certificate, the identifier on the label, the product information in the database, the terminology used in post-market reports and the distributor's actual sales scope are inconsistent, risks will arise in subsequent reviews, recalls or certificate renewals.

AIMEILI recommends that companies establish a global product master data table as early as possible, covering at least product name, model and specification, intended use, risk class, certificate number, UDI or traceability code, label version, countries of sale, local responsible entity and post-market reporting requirements. In markets such as the EU, Australia, the United States, Canada and Singapore, product data governance capability will increasingly affect companies' registration efficiency and ability to maintain continuous market supply.

Business Impact

This update may affect companies' assessment of registration pathways, technical file preparation, labels and instructions for use, quality system records and post-market maintenance arrangements. Companies should conduct an internal assessment based on target markets, product risk class, existing certificates and sales plans, rather than treating regulatory news as general information only.

Compliance Actions for Manufacturers

• Confirm whether the update affects existing registration pathways, certificate maintenance or post-market obligations.
• Verify technical files, labels and instructions for use, quality systems and local responsible entity arrangements in the target countries.
• Establish change impact assessments and regulatory update tracking records for products already on the market.
• Where necessary, archive the official source text, Chinese-language interpretation and internal action items for future audits and project reviews.

Content Review and Scope

Content author: AIMEILI Regulatory Editorial Team. Professional review: AIMEILI Medical Device International Registration Project Team.

Source principles: Priority is given to official regulatory authorities, international organizations, standards bodies and publicly available regulatory materials; industry media and project experience are used only as supporting references.

Scope: This article is intended for preliminary understanding, document preparation and project planning. It does not replace the formal requirements of the target country's regulatory authority, testing conclusions or legal advice.